Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-programmed Death-1 Antibody”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Early research (Phase 1)Active Not RecruitingNCT02715284
What this trial is testing

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
Tesaro, Inc. 730
Testing effectiveness (Phase 2)Study completedNCT02659384
What this trial is testing

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 122
Large-scale testing (Phase 3)Study completedNCT03357952
What this trial is testing

JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 10
Large-scale testing (Phase 3)UnknownNCT05661240
What this trial is testing

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd 348
Large-scale testing (Phase 3)Looking for participantsNCT04778956
What this trial is testing

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal CarcinomaPD-1Surgery
Sun Yat-sen University 218
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07457177
What this trial is testing

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Who this might be right for
NK T-Cell Lymphoma
LIANG WANG 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT06449222
What this trial is testing

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Who this might be right for
Locally Advanced Breast CancerTriple Negative Breast CancerMetastatic Triple Negative Breast Cancers
BioNTech SE 83
Large-scale testing (Phase 3)Active Not RecruitingNCT02362594
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 1,019
Testing effectiveness (Phase 2)Study completedNCT04068519
What this trial is testing

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Who this might be right for
Advanced Solid Tumors
BeiGene 300
Early research (Phase 1)Active Not RecruitingNCT02651662
What this trial is testing

Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Lymphoma
Regeneron Pharmaceuticals 105
Testing effectiveness (Phase 2)Active Not RecruitingNCT06449209
What this trial is testing

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Who this might be right for
Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
BioNTech SE 110
Testing effectiveness (Phase 2)Study completedNCT02834052
What this trial is testing

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Who this might be right for
Metastatic Colon CancerSolid Tumor
Asha Nayak 42
Testing effectiveness (Phase 2)UnknownNCT02886897
What this trial is testing

Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaBladder Cancer+3 more
Sun Yat-sen University 50
Large-scale testing (Phase 3)Looking for participantsNCT05340491
What this trial is testing

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 212
Testing effectiveness (Phase 2)Study completedNCT03910660
What this trial is testing

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Who this might be right for
Prostate CancerNeuroendocrine TumorsSmall Cell Carcinoma
BioXcel Therapeutics Inc 98
Early research (Phase 1)Study completedNCT01358721
What this trial is testing

Phase I Biomarker Study (BMS-936558)

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 119
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Not applicableUnknownNCT05310305
What this trial is testing

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Who this might be right for
Immune Checkpoint InhibitorsAnti-programmed Death-1 AntibodyRadiotherapy+7 more
Lei Li 20
Testing effectiveness (Phase 2)Study completedNCT04521348
What this trial is testing

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Who this might be right for
Thyroid Cancer
Fudan University 103
Load More Results